1-苯基哌啶-3-甲酰胺 | 58971-08-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苯基哌啶-3-甲酰胺
• 英文名称: 1-phenylpiperidine-3-carboxamide
• 英文别名: 1-phenyl-piperidine-3-carboxylic acid amide
• CAS: 58971-08-7
• 化学式: C₁₂H₁₆N₂O
• 分子量: 204.272
• InChiKey: WWKZWKKEYNZSQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010059658A1

  公开（公告）日：2010-05-27

  The invention is directed to 6-(4-pyιϊmidinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及6-(4-吡咯嗪基)-1 H-吲唑衍生物。具体而言，该发明涉及符合式(I)的化合物，其中R1-R4在此处被定义。该发明的化合物是PDK1的抑制剂，可用于治疗由于恒定激活的ACG激酶所特征化的免疫和代谢性疾病和紊乱，如癌症，更具体地说是乳腺癌、结肠癌和肺癌。因此，该发明进一步涉及包括该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包括该发明化合物的药物组合物来抑制PDK1活性和治疗相关疾病的方法。
• N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS
  申请人：INCYTE CORPORATION

  公开号：EP1758580A2

  公开（公告）日：2007-03-07
• EP1758580A4
  申请人：——

  公开号：EP1758580A4

  公开（公告）日：2008-01-16
• CHEMICAL COMPOUNDS
  申请人：GlaxoSmithKline LLC

  公开号：EP2362775A1

  公开（公告）日：2011-09-07
• [EN] N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PIPERIDINES A SUBSTITUTION N ET UTILISATION DE CES DERNIERES EN TANT QUE SUBSTANCES PHARMACEUTIQUES
  申请人：INCYTE CORP

  公开号：WO2006012226A2

  公开（公告）日：2006-02-02

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type I and/or diseases associated with aldosterone excess.